Scott Requadt - Sep 10, 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TALS)

Role
Chief Executive Officer, Director
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Stock symbol
TALS
Transactions as of
Sep 10, 2022
Transactions value $
$0
Form type
4
Date filed
9/13/2022, 04:30 PM
Previous filing
Aug 2, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Award $0 +80K +15.68% $0.00 590K Sep 10, 2022 Direct F1, F2
holding TALS Common Stock 450K Sep 10, 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F2 Includes 1,509 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F3 These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.